Monitoring Vitamin B12 in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases.

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as a randomized controlled trial.

In a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET, whose participants were characterized by different components of metabolic syndrome, the researchers tested the effect of MET on serum levels of B12, holo transcobalamin II (holo-TC-II), and methylmalonic acid (MMA).

Who Took Part

The study group was 165 women.

The age groups tagged for this paper are middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and pilot study.

Random assignment meant chance, not the researchers, decided who got Cyanocobalamin (Vitamin B12) and who got the comparison, which limits bias.

Some women received a placebo instead of Cyanocobalamin (Vitamin B12), giving a reference point.

It is described as a pilot, a small early test of whether a larger Cyanocobalamin (Vitamin B12) study would be practical.

What Was Measured

In a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET, whose participants were characterized by different components of metabolic syndrome, the researchers tested the effect of MET on serum levels of B12, holo transcobalamin II (holo-TC-II), and methylmalonic acid (MMA).

PubMed files the paper under topics including Breast Neoplasms, Diet, Mediterranean, Hypoglycemic Agents, Metformin, Methylmalonic Acid, Pilot Projects and Risk Factors.

Author keywords: holotranscobalamin II and vitamin B12.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and pilot study of Cyanocobalamin (Vitamin B12) in 165 women.

The publication is from 2019 (Nutrients), a journal based in Switzerland.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.